CRESCENT BIOPHARMA INC (CBIO) — insider trading
Health Care · NASDAQ
CRESCENT BIOPHARMA INC (CBIO) has 23 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 16 open-market sales among the most recent 23 (latest 2026-09-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | McNeill Jonathan | Officer (President and COO) | Open-market sale | 3,839 | $16.71 | $64.1K | Form 4 |
| 2026-09-18 | Brumm Joshua T | Director, Officer (Chief Executive Officer) | Open-market sale | 7,837 | $16.71 | $131.0K | Form 4 |
| 2026-09-16 | Lynch Ryan | Officer (See Remarks) | Open-market sale | 240 | $17.90 | $4.3K | Form 4 |
| 2026-09-16 | Pinkas Jan | Officer (Chief Scientific Officer) | Open-market sale | 658 | $17.90 | $11.8K | Form 4 |
| 2026-09-16 | Im Ellie Eunkyung | Officer (Chief Medical Officer) | Open-market sale | 623 | $17.90 | $11.2K | Form 4 |
| 2026-09-16 | Scalzo Richard William | Officer (Chief Financial Officer) | Open-market sale | 568 | $17.90 | $10.2K | Form 4 |
| 2026-09-16 | McNeill Jonathan | Officer (President and COO) | Open-market sale | 731 | $17.90 | $13.1K | Form 4 |
| 2026-09-16 | Brumm Joshua T | Director, Officer (Chief Executive Officer) | Open-market sale | 1,610 | $17.90 | $28.8K | Form 4 |
| 2026-09-16 | Bispham Barbara Harlin | Officer (See Remarks) | Open-market sale | 620 | $17.90 | $11.1K | Form 4 |
| 2026-07-16 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Open-market purchase (derivative) | 525,897 | $14.50 | $7.62M | Form 4 |
| 2026-07-16 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Open-market purchase | 853,450 | $14.50 | $12.38M | Form 4 |
| 2026-06-22 | Brumm Joshua T | Director, Officer (Chief Executive Officer) | Open-market sale | 42,305 | $17.99 | $761.1K | Form 4 |
| 2026-06-22 | McNeill Jonathan | Officer (President and COO) | Open-market sale | 20,549 | $17.99 | $369.7K | Form 4 |
| 2026-06-22 | Im Ellie Eunkyung | Officer (Chief Medical Officer) | Open-market sale | 1,219 | $17.99 | $21.9K | Form 4 |
| 2026-06-22 | Bispham Barbara Harlin | Officer (See Remarks) | Open-market sale | 1,218 | $17.99 | $21.9K | Form 4 |
| 2026-06-22 | Scalzo Richard William | Officer (Chief Financial Officer) | Open-market sale | 1,112 | $17.99 | $20.0K | Form 4 |
| 2026-06-22 | Pinkas Jan | Officer (Chief Scientific Officer) | Open-market sale | 1,288 | $17.99 | $23.2K | Form 4 |
| 2026-06-22 | Lynch Ryan | Officer (See Remarks) | Open-market sale | 465 | $17.99 | $8.4K | Form 4 |
| 2026-06-02 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | Director, 10% owner | Grant / award / vesting (derivative) | 11,050 | — | $0 | Form 4 |
| 2026-06-02 | Moran Susan | Director | Grant / award / vesting (derivative) | 11,050 | — | $0 | Form 4 |
| 2026-06-02 | Balcom Alexandra | Director | Grant / award / vesting (derivative) | 11,050 | — | $0 | Form 4 |
| 2026-06-02 | Lubner David Charles | Director | Grant / award / vesting (derivative) | 11,050 | — | $0 | Form 4 |
| 2026-06-02 | Violin Jonathan | Director | Grant / award / vesting (derivative) | 11,050 | — | $0 | Form 4 |
Ask the chat about CBIO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CRESCENT BIOPHARMA INC (CBIO).
Last updated 2026-09-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.